Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer

Overview of attention for article published in Frontiers in immunology, October 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 8 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 52,361 followers.

New article: Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer https://t.co/o4NlCC4SMa #uterinecancer #oncology https://t.co/5k2HcqJIH5

25 Oct 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-…

07 Oct 2022

Reply Repost Favourite

Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer: With the widespread use of immune checkpoint inhibitors (ICI), there is… #immunology https://t.co/uDWJ

06 Oct 2022

Reply Repost Favourite

New Research: Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer: With the widespread use of immune checkpoint inhibitors (ICI), there is… https://t.co/pJt

06 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.